蒋平,关伟,戴楠,等.DNA损伤修复基因以及TS、β-tubulinⅢ在骨肉瘤中的表达及其与临床病理的关系[J].第三军医大学学报,2013,35(01):61. Jiang Ping,Guan Wei,Dai Nan,et al.Expression of DNA damage repair genes, thymidylate synthase and β-tubulin Ⅲ in human osteosarcoma tissues and its relationship with clinical pathology of osteosarcoma[J].J Third Mil Med Univ,2013,35(08):61. [2]温磊,孟刚,李懿,等.人骨肉瘤抗失巢凋亡细胞的生物学特性研究[J].第三军医大学学报,2008,30(10):942. WEN Lei,MENG Gang,LI Yi,et al.Biological characteristics of anoikis-resistant cells from human osteosarcoma cell line hFOB1.19[J].J Third Mil Med Univ,2008,30(08):942. [3]李懿,孟刚,郭乔楠.P53和P63蛋白在人骨肉瘤组织及恶性转化细胞株中的表达变化及意义[J].第三军医大学学报,2006,28(08):763. [4]仲召阳,王东,李增鹏,等.骨肉瘤中APE1的表达及其与血管生成的关系[J].第三军医大学学报,2005,27(10):1045. [5]卫佳,李星星,陈英华,等.β-catenin降低外源性hS100A6对骨肉瘤细胞的抑制作用[J].第三军医大学学报,2010,32(16):1703. Wei Jia,Li Xingxing,Chen Yinghua,et al.β-catenin decreases hS100A6-induced inhibition in osteosarcoma cell lines MG63 and U2OS[J].J Third Mil Med Univ,2010,32(08):1703. [6]何畔,梁珊.RNAi抑制XIAP基因诱导MG63细胞凋亡、化疗增敏及其分子机制[J].第三军医大学学报,2010,32(12):1312. He Pan,Liang Shan.RNAi silencing of XIAP gene induces apoptosis and susceptibility to chemotherapy of osteosarcoma cell line MG63[J].J Third Mil Med Univ,2010,32(08):1312. [7]曾静,温磊,黄玉胜,等.神经营养因子酪氨酸激酶受体B对人永生化成骨细胞hFOB1.19恶性转化细胞体外侵袭力的影响[J].第三军医大学学报,2010,32(09):938. Zeng Jing,Wen Lei,Huang Yusheng,et al.Effect of neurotrophic tyrosine kinase receptor B on in vitro invasiveness of malignant transformed hFOB1.19 cells[J].J Third Mil Med Univ,2010,32(08):938. [8]洪思琦,毕杨,郭振华,等.携带siANGPTL4重组腺病毒的构建及其对MG63增殖的抑制作用[J].第三军医大学学报,2011,33(01):28. Hong Siqi,Bi Yang,Guo Zhenhua,et al.Construction of recombinant adenovirus with siANGPTL4 gene and its inhibitive effect on MG63 cell proliferation[J].J Third Mil Med Univ,2011,33(08):28. [9]张樨,吕杨帆,戴欢子,等.RanBP9的表达对骨肉瘤细胞增殖、凋亡及转移的影响[J].第三军医大学学报,2014,36(08):745. Zhang Xi,Lyu Yangfan,Dai Huanzi,et al.Effect of RanBP9 expression on proliferation，apoptosis and metastasis in human osteosarcoma cells[J].J Third Mil Med Univ,2014,36(08):745. [10]高天,郭乔楠.整合素β1在骨肉瘤中的表达及其临床意义[J].第三军医大学学报,2005,27(18):1863.
